Prognostic impact of biomarkers in PMBCL: rationale for early integration of immune checkpoint inhibitors
Yana K. Mangasarova , Runiza R. Abdurashidova , Natalya V. Risinskaya , Bella V. Biderman , Tatiana V. Abramova , Vadim L. Surin , Irina A. Shupletsova , Tatiana N. Obukhova , Rasul I. Iusupov , Yulia A. Chabaeva , Aminat U. Magomedova , Lena E. Nikulina , Sergei M. Kulikov , Eugene E. Zvonkov , Alla M. Kovrigina , Andrey B. Sudarikov
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002318
Aim: This research aims to guide future strategies for personalized treatment of primary mediastinal large B-cell lymphoma (PMBCL), particularly to identify high-risk patients who may benefit from incorporating immune checkpoint inhibitors (ICIs) in the first-line setting.
Methods: A retrospective, single-center study included 254 newly diagnosed PMBCL patients treated with rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (R-DA-EPOCH), rituximab, modified protocol NHL-BFM-90 (RmNHL-BFM-90), or R-DA-EPOCH combined with nivolumab. Clinical parameters, immunohistochemical markers [programmed death ligand-1 (PD-L1), programmed death-1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), human leucocyte antigen (HLA)-DR, Ki-67, multiple myeloma oncogene 1 (MUM1)], molecular markers (mutations in tumor protein p53 (TP53), CD58, beta-2-microglobulin (B2M), and exportin 1 (XPO1) genes; short tandem repeats at 6p21.3 [major histocompatibility complex (MHC) class I/II], 9p24.1 (PD-L1/PD-L2), 16p13.13 [class II, MHC, transactivator gene (CIITA)]), and cytogenetic profiles [myelocytomatosis oncogene (MYC)/8q24, B-cell lymphoma 2 (BCL2)/18q21, BCL6/3q27, del17p13, and karyotype abnormalities] were analyzed.
Results: The addition of nivolumab to R-DA-EPOCH as a first-line regimen significantly improved event-free survival (EFS; P = 0.018). This study identified that adverse prognostic factors for PMBCL include allelic imbalance at specific loci 6p21.3 (MHC class I/II), 9p24.1 (PD-L1/PD-L2), and 16p13.13 (CIITA). Incorporating nivolumab into the R-DA-EPOCH regimen as a first-line therapy has shown potential in reducing adverse prognostic factors.
Conclusions: These findings suggest that high-risk patients may benefit significantly from the early incorporation of ICIs into their treatment plans.
PMBCL / immune checkpoint inhibitors / loss of heterozygosity / genomic instability
| [1] |
|
| [2] |
Camus V, Drieux F, |
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
Vassilakopoulos T, Ferhanoglu B, Horowitz N, Mellios Z, Kaynar L, Zektser M, |
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, |
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
Shin G, |
| [22] |
|
| [23] |
|
| [24] |
Schoumans J, Suela J, Hastings R, Muehlematter D, Rack K, van den Berg E, |
| [25] |
|
| [26] |
ncbi.nlm.nih.gov/gene [Internet]. Bethesda: Courtesy of the National Library of Medicine; [cited 2024 Dec 25]. Available from: https://www.ncbi.nlm.nih.gov/gene/ |
| [27] |
hgvs-nomenclature.org [Internet]. [cited 2024 Dec 25]. Available from: http://varnomen.hgvs.org/ |
| [28] |
SIFT. Version 6.2.1 [Software]. [cited 2024 Dec 25]. Available from: https://sift.bii.a-star.edu.sg/ |
| [29] |
PROVEAN. Version 1.1.5 [Software]. [cited 2024 Dec 25]. Available from: http://provean.jcvi.org/ |
| [30] |
PolyPhen-2. Version 2.2.2 [Software]. [cited 2024 Dec 25]. Available from: http://genetics.bwh.harvard.edu/pph2/ |
| [31] |
MutationTaster [Software]. [cited 2024 Dec 25]. Available from: https://www.mutationtaster.org/ |
| [32] |
ClinVar [Internet]. Bethesda: Courtesy of the National Library of Medicine; [cited 2024 Dec 25]. Available from: https://www.ncbi.nlm.nih.gov/clinvar/ |
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, |
| [38] |
|
| [39] |
RYR2:c.8162T>C [Internet]. [cited 2024 Nov 15]. Available from: https://franklin.genoox.com/variant/snp/chr1-237821276-T-C |
| [40] |
Seshat [Internet]. [cited 2024 Nov 15]. Available from: http://vps338341.ovh.net/ |
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
/
| 〈 |
|
〉 |